Sign inJoin waitlistJoin the waitlist

Martha Arellano

Director, Hematology and Medical Oncology Fellowship Program · Emory University School of Medicine

Credentials: · · ·

History

Emory University School of Medicine
Present
Emory University School of Medicine
Present

Hematology and Medical Oncology
Emory University School of Medicine
2003–2006
Internal Medicine
Emory University School of Medicine
2000–2001
Emory University School of Medicine
1996–2000

Research

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Blood · 2019 · 1,529 citations
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
New England Journal of Medicine · 2018 · 1,234 citations
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
The Lancet · 2021 · 704 citations

HK
Hanna Khoury
37 papers
EW
Elliot Winton
21 papers
LH
Leonard Heffner
21 papers
Amelia Langston
19 papers
Sagar Lonial
18 papers
Gary Schiller
16 papers
Edmund Waller
14 papers
Maria Baer
14 papers
ES
Eytan Stein
13 papers
Hagop Kantarjian
12 papers
ET
Elie Traer
11 papers
JF
Jun Fan
11 papers

Clinical trials

Impact of a Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) by Maintaining a Database
Principal investigator · Terminated
Emory University
2014–2018
Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60
Principal investigator · Terminated · Phase 1
Emory University
2013–2016
Omacetaxine for Consolidation and Maintenance
Principal investigator · Terminated · Phase 2
Emory University
2013–2018
Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
Principal investigator · Completed · Phase 2
Emory University
2007–2015